10 terminated, 7 active not recruiting, 5 completed, 5 recruiting. 18 Phase 1, 17 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Y-mAbs Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) 25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-07-02 | 2026-10-08 |
| Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Naxitamab - High-Risk Neuroblastoma | Phase 2 | Recruiting | Shaare Zedek Medical Center | 10 | 2026-06-23 | 2026-09-17 |
| Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) Sacituzumab govitecan, Naxitamab - Metastatic Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2025-09-19 | 2026-07-07 |
| Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma Naxitamab, Irinotecan, Temozolomide - Neuroblastoma, Neuroblastoma Recurrent | Phase 1 | Recruiting | Steven DuBois, MD | 18 | 2025-06-27 | 2026-07-14 |
| Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma CD38-SADA:177Lu-DOTA Complex - Non-hodgkin Lymphoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 1 | 2025-04-21 | 2026-03-12 |
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi) - SCLC, Malignant Melanoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 23 | 2022-11-17 | 2026-06-18 |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Naxitamab - Neuroblastoma | Phase 2 | Recruiting | Giselle Sholler | 93 | 2022-09-14 | 2026-08-12 |
| 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) radiolabeled DPTA-omburtamab - Leptomeningeal Metastasis, Solid Tumor, Adult | Phase 1 / Phase 2 | Withdrawn | Y-mAbs Therapeutics | 2022-08-31 | 2022-07-15 | |
| A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia CD33*CD3 BsAb - AML, Childhood | Phase 1 | Terminated | Y-mAbs Therapeutics | 3 | 2022-05-25 | 2023-05-30 |
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma 131I-Omburtamab, Convention Enhanced Delivery - DIPG | Phase 1 | Withdrawn | Y-mAbs Therapeutics | 2022-03-01 | 2023-06-26 | |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. Naxitamab, GM-CSF, Isotretinoin - Neuroblastoma | Phase 2 | Withdrawn | Y-mAbs Therapeutics | 2021-12-02 | 2022-09-01 | |
| Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma Naxitamab and GM-CSF in combination with irinotecan and temozolomide - Neuroblastoma Recurrent | Phase 2 | Terminated | Y-mAbs Therapeutics | 2 | 2021-11-08 | 2024-03-18 |
| 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma 177Lu-DTPA-omburtamab - Medulloblastoma, Childhood | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 2 | 2021-09-30 | 2023-10-06 |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer Nivatrotamab - SCLC | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 3 | 2021-08-17 | 2023-08-14 |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum 131 I-omburtamab, WAP-IMRT - Desmoplastic Small Round Cell Tumor, Peritoneal Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2019-07-15 | 2026-07-21 |
| Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Humanized 3F8 Bispecific Antibody, Blood draw - Neuroblastoma, Osteosarcoma | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 12 | 2019-02-22 | 2023-09-13 |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases 131I-omburtamab - Neuroblastoma, CNS Metastases | Phase 2 / Phase 3 | Terminated | Y-mAbs Therapeutics | 52 | 2018-12-11 | 2024-02-13 |
| Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow GM-CSF + Naxitamab - Neuroblastoma | Phase 2 | Active not recruiting | Y-mAbs Therapeutics | 122 | 2018-04-03 | 2026-07-30 |
| Study of Chemoimmunotherapy for High-Risk Neuroblastoma Irinotecan, temozolomide, Hu3F8 - Neuroblastoma (NB) | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2017-06-12 | 2026-07-06 |
Showing 20 of 31. Sign in to see all of them.
Neuroblastoma (16) · Medulloblastoma (5) · Meningeal Carcinomatosis (3) · Osteosarcoma (3) · Sarcoma (3) · Brain Neoplasms (2) · Desmoplastic Small Round Cell Tumor (2) · Melanoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Central Nervous System Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Hepatoblastoma (1) · Leukemia, Myeloid, Acute (1)
naxitamab (12) · Granulocyte-Macrophage Colony-Stimulating Factor (8) · omburtamab I-131 (5) · Irinotecan (4) · Temozolomide (4) · Isotretinoin (2) · humanized 3F8 anti-GD2 monoclonal antibody (2) · Antiemetics (1) · Antipyretics (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Dexamethasone (1) · Histamine Antagonists (1)
United States (27) · Spain (4) · Denmark (3) · Hong Kong (3) · United Kingdom (3) · Canada (2) · South Korea (2) · Brazil (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Russia (1)
Shakeel Modak, MD (4) · Brian Kushner, MD (2) · Brian H. Kushner, MD (1) · Clinton Yam, MD (1) · Ellen Basu, MD,PhD (1) · Emily Slotkin, MD (1) · Filemon Dela Cruz, MD (1) · Iris Fried, MD (1) · Jaqueline Kraveka, DO (1) · Jessica Pollard, MD (1) · John Roemer, MD (1) · Kim Kramer, MD (1) · Mark Souweidane, MD (1) · Matthias Karajannis, MD, MS (1) · Sameer Farouk Sait, MBBS (1)
PMID 31401903, PMID 24520094, PMID 26939629, PMID 28686124, PMID 29147617, PMID 29914796, PMID 30326045, PMID 30579270, PMID 32977309, PMID 33047248, PMID 33119478, PMID 33326254, PMID 36371226, PMID 36547975, PMID 38464207, PMID 39083105, PMID 39142829, PMID 39969230, PMID 40067131, PMID 40306974, PMID 41299684, PMID 41670398
UM1CA081457 (1)